The diagnosis of soft tissue tumors is challenging, especially when the evaluable material procured is limited. As a result, diagnostic ancillary testing is frequently needed. Moreover, there is a trend in soft tissue pathology toward increasing use of molecular results for tumor classification and prognostication. Hence, diagnosing newer tumor entities such as CIC-rearranged sarcoma explicitly requires molecular testing. Molecular testing can be accomplished by in situ hybridization, polymerase chain reaction, as well as next generation sequencing, and more recently such testing can even be accomplished leveraging an immunohistochemical proxy.

中文翻译：

---

软组织肿瘤的分子检测

软组织肿瘤的诊断具有挑战性，尤其是当获得的可评估材料有限时。因此，经常需要诊断辅助测试。此外，软组织病理学有越来越多地使用分子结果进行肿瘤分类和预测的趋势。因此，诊断较新的肿瘤实体（例如 CIC 重排肉瘤）明确需要分子检测。分子检测可以通过原位杂交、聚合酶链式反应以及下一代测序来完成，最近这种检测甚至可以利用免疫组织化学代理来完成。